Oncorus, Inc.

mpmcapital.com

Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.